88 related articles for article (PubMed ID: 3092531)
1. Analysis of human myeloma cell population kinetics.
Montecucco C; Riccardi A; Ucci G; Danova M; Carnevale R; Caporali R; Longhi M; Luoni R
Acta Haematol; 1986; 75(3):153-6. PubMed ID: 3092531
[TBL] [Abstract][Full Text] [Related]
2. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.
Boccadoro M; Marmont F; Tribalto M; Fossati G; Redoglia V; Battaglio S; Massaia M; Gallamini A; Comotti B; Barbui T
J Clin Oncol; 1989 Jan; 7(1):119-25. PubMed ID: 2909664
[TBL] [Abstract][Full Text] [Related]
3. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
[TBL] [Abstract][Full Text] [Related]
4. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis.
Gertz MA; Kyle RA; Greipp PR
Blood; 1989 Aug; 74(3):1108-11. PubMed ID: 2752156
[TBL] [Abstract][Full Text] [Related]
5. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
6. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
Kumar S; Rajkumar SV; Greipp PR; Witzig TE
Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
[TBL] [Abstract][Full Text] [Related]
7. Ploidy and proliferative characteristics in monoclonal gammopathies.
Latreille J; Barlogie B; Johnston D; Drewinko B; Alexanian R
Blood; 1982 Jan; 59(1):43-51. PubMed ID: 6172171
[TBL] [Abstract][Full Text] [Related]
8. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio.
Riccardi A; Montecucco C; Danova M; Ucci G; Merlini G; Ascari E
Cancer Treat Rep; 1985 Sep; 69(9):971-5. PubMed ID: 4028038
[TBL] [Abstract][Full Text] [Related]
9. Proliferation kinetics of plasma cells and of normal haemopoietic cells in multiple myeloma.
Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R; Montecucco CM; Ciotti R; Girino M
Cell Tissue Kinet; 1987 May; 20(3):311-8. PubMed ID: 3480077
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
11. Growth kinetics of plasma cell myeloma.
Drewinko B; Alexanian R
J Natl Cancer Inst; 1977 May; 58(5):1247-53. PubMed ID: 857025
[TBL] [Abstract][Full Text] [Related]
12. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.
Durie BG; Young LA; Salmon SE
Blood; 1983 May; 61(5):929-34. PubMed ID: 6831055
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.
Boccadoro M; Omedé P; Dominietto A; Palumbo A; Bringhen S; Giaretta F; Ortolano B; Triolo S; Pileri A
Bone Marrow Transplant; 2000 Jan; 25(1):25-9. PubMed ID: 10654010
[TBL] [Abstract][Full Text] [Related]
14. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
15. Early plasma cell recruitment in multiple myeloma following chemotherapy.
Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
[TBL] [Abstract][Full Text] [Related]
16. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
17. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Rajkumar SV
Am J Hematol; 2013 Mar; 88(3):226-35. PubMed ID: 23440663
[TBL] [Abstract][Full Text] [Related]
18. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
[TBL] [Abstract][Full Text] [Related]
19. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).
Greipp PR; Witzig TE; Gonchoroff NJ
Am J Hematol; 1985 Nov; 20(3):289-92. PubMed ID: 3904417
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
Boccadoro M; Gallamini A; Fruttero A; Gavarotti P; Redoglia V; Buffa F; Ruá S; Pileri A
J Clin Oncol; 1985 Nov; 3(11):1503-7. PubMed ID: 4056842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
